JP3946239B1 - Accelerating pulse wave aging index raising agent - Google Patents

Accelerating pulse wave aging index raising agent Download PDF

Info

Publication number
JP3946239B1
JP3946239B1 JP2006183236A JP2006183236A JP3946239B1 JP 3946239 B1 JP3946239 B1 JP 3946239B1 JP 2006183236 A JP2006183236 A JP 2006183236A JP 2006183236 A JP2006183236 A JP 2006183236A JP 3946239 B1 JP3946239 B1 JP 3946239B1
Authority
JP
Japan
Prior art keywords
pulse wave
aging index
acceleration pulse
start
wave aging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2006183236A
Other languages
Japanese (ja)
Other versions
JP2008013443A (en
Inventor
忠士 江藤
Original Assignee
株式会社日本バリアフリー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社日本バリアフリー filed Critical 株式会社日本バリアフリー
Priority to JP2006183236A priority Critical patent/JP3946239B1/en
Priority claimed from KR1020070066257A external-priority patent/KR101301037B1/en
Application granted granted Critical
Publication of JP3946239B1 publication Critical patent/JP3946239B1/en
Publication of JP2008013443A publication Critical patent/JP2008013443A/en
Active legal-status Critical Current

Links

Images

Abstract

The present invention provides a new use of components extracted from ovarian membranes of fish.
A peripheral blood flow-improving agent containing a component extracted from the ovarian membrane of fish, which can alleviate and improve various symptoms caused by a decrease in peripheral blood circulation. The component extracted from the ovarian membrane is a component extracted by treating the ovarian membrane with a proteolytic enzyme. The ovarian membrane is a spider ovarian membrane.
[Selection] Figure 1

Description

The present invention relates to an acceleration pulse wave aging index raising agent .

  Conventionally, a method of extracting amino acids and peptides by treating the ovarian membrane (fish egg rind) of fish with ozone water in advance and then enzymatically degrading myofibrillar protein, which is a constituent protein thereof, is known (for example, patent document). 1).

  The amino acids and peptides can be used as physiologically active substances or as food fortifiers. More specifically, the amino acids and peptides have ACE inhibitory activity and act as blood pressure increase inhibitors (hypertensive agents).

However, it is desired to develop more uses for the components extracted from the ovarian membrane of fish.
JP 2004-73186 A

  In view of such circumstances, an object of the present invention is to provide a new use of a component extracted from the ovarian membrane of fish.

In order to achieve this object, the accelerated pulse wave aging index increasing agent of the present invention is characterized by containing a component extracted by treating the ovarian membrane of sputum with a proteolytic enzyme .

  In the living body, after the adulthood, with aging, various symptoms appear due to a decrease in peripheral blood circulation such as rough skin, stiff shoulders, joint pain, swelling, coldness and anemia. The decrease in peripheral blood circulation is caused not only by the above-mentioned aging but also by low blood pressure, a decrease in heart pump function, muscle shortage, and the like. The decrease in the peripheral blood circulation is grasped as a decrease in the acceleration pulse wave aging index.

  The acceleration pulse wave aging index is an index indicating the flexibility of peripheral blood vessels. For example, the fingertip is a folded portion where blood pumped from the heart passes through an artery and reaches a vein. By measuring the change in the volume (volume) of blood flowing in the peripheral blood vessels of the fingertips, the expansion / contraction state of the peripheral blood vessels can be obtained as a waveform, and this waveform is called “fingertip pulse wave”. An acceleration pulse wave showing a waveform of the systole of the heart is obtained by second-order differentiation of the fingertip pulse wave. For example, the acceleration pulse wave shown in FIG. 6 has four waves, the a wave being the initial contraction positive wave, the b wave being the initial contraction negative wave, the c wave being the middle systolic re-rising wave, and the d wave being the late systolic re-falling wave. . The a wave and the b wave depend on the driving pressure wave generated by the ejection of blood, and the c wave and the d wave depend on the reflected pressure wave that the driving pressure wave propagates to the periphery and is reflected back. The acceleration pulse wave aging index is obtained from the waveform of the acceleration pulse wave by the formula “{(−b + c + d) / a} × 100”. Note that “a”, “b”, “c”, and “d” in the previous equation are the heights of the a wave, b wave, c wave, and d wave. The acceleration pulse wave aging index generally takes a value of −120 to 120, and the higher the value, the more flexible the peripheral blood vessels and the better the peripheral blood circulation.

The inventors of the present application ingested the accelerated pulse wave aging index increasing agent of the present invention, and examined the peripheral blood circulation state using the accelerated pulse wave aging index, various symptoms due to a decrease in peripheral blood circulation It was found that this can be relaxed and improved.

Next, embodiments of the present invention will be described in more detail with reference to the accompanying drawings. FIG. 1 is a graph showing a comparison between the physical condition after ingesting the acceleration pulse wave aging index increasing agent of this embodiment for 8 weeks and the physical condition after 2 weeks from the discontinuation of intake, and FIG. 2 is an acceleration pulse wave addition of this embodiment. FIG. 3 is a graph showing the change over time of the acceleration pulse wave aging index when taking an age index increasing agent and when taking a placebo (placebo), FIG. 3 is taking the acceleration pulse wave aging index increasing agent of this embodiment FIG. 4 is a graph showing the amount of change in the acceleration pulse wave aging index when taking a placebo and when taking a placebo, and FIG. 4 shows the case where the acceleration pulse wave aging index increasing agent of this embodiment is taken and the placebo is taken FIG. 5 is a graph showing the amount of change in IGF-1 value when the accelerated pulse wave aging index raising agent of this embodiment is ingested and when the placebo is ingested. is there.

The acceleration pulse wave aging index increasing agent of the present embodiment contains a component extracted from the ovarian membrane of rabbit (hereinafter abbreviated as an ovarian membrane extraction component). The ovarian membrane extract component can be obtained by, for example, a method of filtering a solution obtained by enzymatic treatment of salmon ovarian membrane and drying the obtained filtrate.

  Specifically, in the method, first, the ovarian membrane of the pupa is used as a raw material, and water is added to the ovarian membrane in a weight ratio of ovarian membrane: water = 1: 1 to 1: 3, and the mixture is stirred and mixed. Furthermore, a proteolytic enzyme is added in the range of 1 to 3% by weight with respect to the total amount of the ovarian membrane, and heated at a temperature of 45 to 55 ° C. for 30 minutes to 5 hours, preferably 2 hours. If it does in this way, the component decomposed | disassembled with the said proteolytic enzyme will elute in water among the components of the said ovary membrane, and the aqueous solution of this component will be obtained.

  Next, the proteolytic enzyme contained in the aqueous solution is inactivated. The deactivation can be performed, for example, by heating the aqueous solution at a temperature of 90 ° C. for 5 minutes.

  Next, the aqueous solution is simply filtered through a wire mesh of about 30 mesh to remove coarse materials such as undecomposed ovarian membranes. Then, activated carbon is added to the obtained filtrate to deodorize, decolorize, and degrease the filtrate. The deodorization, decolorization, and degreasing of the filtrate is performed by adding activated carbon in the range of 2 to 4% by weight to the total amount of the ovarian membrane as the raw material and heating the filtrate at a temperature of 60 ° C. for 30 minutes, for example. be able to.

  After the deodorization, decolorization, and degreasing treatment with the activated carbon, the filtrate is filtered by, for example, a filter press, and the obtained filtrate is concentrated at a temperature of 60 ° C. under reduced pressure, for example, and then maintained at a temperature of 80 ° C. for 10 minutes, for example. And sterilize. Then, the ovarian membrane extract component can be obtained by drying the sterilized filtrate by spray drying. The ovarian membrane extract component contains amino acids, peptides, vitamins, minerals, sugars, enzymes, nucleic acids and their metabolites, various growth factors, cytokines, and the like.

The acceleration pulse wave aging index increasing agent of the present embodiment is prepared by formulating the ovarian membrane extract component, for example, in the form of a tablet or the like. For example, by taking it as a food such as a health food, the peripheral blood circulation is reduced. Can alleviate and improve symptoms.

  Next, examples of the present invention and comparative examples will be described.

In this example, first, an ovarian membrane extract component of sputum was formulated in the form of a tablet to produce an acceleration pulse wave aging index raising agent . The tablet consists of 245 mg of the ovarian membrane extract and 5 mg of excipient (Loveli wax (registered trademark)) and has a diameter of 8 mm.

  Next, 10 healthy female monitors aged 38 to 42 years old took 4 tablets per day for 8 weeks as a health food. Each monitor has not taken supplements or medicines (including herbal medicines) since one month ago.

  And about the physical condition by the self-report of each monitor, the state of the 8th week after an intake start and the 2 weeks after an intake stop was compared. The results are shown in FIG.

  Further, before the start of ingestion and 8 weeks after the start of ingestion, the peripheral blood circulation at the tip (fingertip) of the right index finger was examined to obtain an acceleration pulse wave aging index.

  Peripheral blood circulation status was examined as follows. Using an acceleration sphygmograph (BC Checker (registered trademark)) manufactured by Future Wave Inc., the fingertip of the right index finger is brought into contact with the center part. The acceleration pulse wave meter irradiates the fingertip with near-infrared light (wavelength 950 nm), captures the light scattered outside the subcutaneous tissue and absorbed by the blood and then released outside the body, and generates the waveform of the fingertip pulse wave The waveform of the acceleration pulse wave obtained by second-order differentiation of the waveform of the fingertip pulse wave is output. The acceleration pulse wave aging index is obtained from the waveform of the acceleration pulse wave.

  The average value of the acceleration pulse wave aging index of the 10 monitors is shown in FIG. 2, and the amount of change in the average value of the acceleration pulse wave aging index from the start of intake to the 8th week is shown in FIG. In FIG. 2, “0 week” is indicated before the start of ingestion, “8 week” is indicated after the 8th week from the start of ingestion, and “0-8 weeks” is indicated from the start of intake to the 8th week in FIG. 3. To do.

  Further, before the start of ingestion, 4 weeks after the start of ingestion and 8 weeks after the start of ingestion, blood tests were performed to measure insulin growth factor-1 (IGF-1: Insulin-like Growth Factor-1) values. IGF-1 is a polypeptide having a structure very similar to insulin. It is said that the IGF-1 value decreases with aging, and the once lowered IGF-1 value does not increase again.

The average value of IGF-1 values of the 10 monitors is shown in FIG. 4, and the change amount of the average value of IGF-1 values from the start of intake to the 4th week and from the start of intake to the 8th week is shown in FIG. .
[Comparative Example]
In this comparative example, first, a placebo (placebo) consisting of 125 mg of corn starch and 125 mg of lactose was formulated in the form of a tablet having a diameter of 8 mm instead of the acceleration pulse wave aging index raising agent of the above-mentioned example.

  Next, the placebo capsules were administered 4 times a day for 8 weeks to 10 healthy female monitors aged 38 to 42 years different from the Examples. Each monitor has not taken supplements or medicines (including herbal medicines) since one month ago.

  Then, the acceleration pulse wave aging index and the IGF-1 value were measured in exactly the same manner as in the above example. FIG. 2 shows the average value of the acceleration pulse wave aging index of the 10 monitors, FIG. 3 shows the amount of change in the average value of the acceleration pulse wave aging index 8 weeks after the start of intake, and FIG. FIG. 4 shows the average value of 1 values, and FIG. 5 shows the amount of change in the average value of IGF-1 values after 4 weeks from the start of intake and 8 weeks after the start of intake.

From Figure 1, according to the acceleration pulse wave aging index increasing agent of the present embodiment (Example), the acceleration pulse wave aging index increasing agent of the present embodiment from the start of ingestion than physical condition after 2 weeks intake discontinued It is clear that the physical condition at 8 weeks is superior.

Therefore, it is considered that various symptoms due to the decrease in peripheral blood circulation were alleviated and improved by taking the acceleration pulse wave aging index increasing agent of this embodiment. Moreover, it is thought that it is effective to ingest the acceleration pulse wave aging index raising agent of this embodiment continuously.

In addition, from FIG. 2, according to the acceleration pulse wave aging index increasing agent of the present embodiment, the acceleration pulse wave aging index is increased in the 8th week from the start of intake compared to before the start of intake. it is obvious. On the other hand, according to the placebo (comparative example), it is clear that in the 8th week from the start of intake, it is lower than that before the start of intake.

Moreover, it is clear from FIG. 3 that according to the acceleration pulse wave aging index increasing agent of the present embodiment, the acceleration pulse wave aging index increases greatly.

Therefore, it is considered that the flexibility of peripheral blood vessels has been improved by taking the acceleration pulse wave aging index increasing agent of the present embodiment.

Furthermore, from FIG. 4, according to the acceleration pulse wave aging index increasing agent of this embodiment, the IGF-1 value increased compared to before the start of intake at 4 weeks from the start of intake, and from the start of intake. At 8 weeks, it is further increased from 4 weeks after the start of ingestion, and it is clear that it is increasing monotonously. On the other hand, according to the placebo, although the IGF-1 value increased in the 8th week from the start of the intake compared to before the start of the intake, it was compared in the 4th week after the start of the intake before the start of the intake. It is clear that the IGF-1 value has decreased once, not a monotonous increase.

Moreover, from FIG. 5, according to the acceleration pulse wave aging index raising agent of this embodiment, it is clear that the increase amount of IGF-1 value is larger than a placebo.

Therefore, it is considered that the IGF-1 value increased by taking the acceleration pulse wave aging index increasing agent of the present embodiment. In addition, the above-described alleviation and improvement of various symptoms due to the decrease in peripheral blood circulation is considered to be caused by an increase in IGF-1 level.

The graph which shows the comparison with the physical condition after ingesting the acceleration pulse wave aging index raising agent which concerns on this invention for 8 weeks, and the physical condition after 2 weeks from ingestion. The graph which shows the time-dependent change of the acceleration pulse wave aging index | exponent when the case where the acceleration pulse wave aging index raising agent which concerns on this invention is ingested, and the case where a placebo (placebo) is ingested. The graph which shows the variation | change_quantity of the acceleration pulse wave aging index of the case where the acceleration pulse wave aging index raising agent which concerns on this invention is ingested, and the case where a placebo is ingested. The graph which shows the time-dependent change of the IGF-1 value at the time of ingesting the case where the acceleration pulse wave aging index raising agent which concerns on this invention is ingested, and the placebo. The graph which shows the variation | change_quantity of the IGF-1 value when the case where the acceleration pulse wave aging index raising agent which concerns on this invention is ingested, and the placebo is ingested. The graph which shows an example of an acceleration pulse wave.

Explanation of symbols

  No sign.

Claims (1)

  1. Accelerating pulse wave aging index increasing agent characterized by containing a component extracted by treating ovarian ovarian membrane with proteolytic enzyme .
JP2006183236A 2006-07-03 2006-07-03 Accelerating pulse wave aging index raising agent Active JP3946239B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006183236A JP3946239B1 (en) 2006-07-03 2006-07-03 Accelerating pulse wave aging index raising agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006183236A JP3946239B1 (en) 2006-07-03 2006-07-03 Accelerating pulse wave aging index raising agent
KR1020070066257A KR101301037B1 (en) 2006-07-03 2007-07-02 Antiaging agent

Publications (2)

Publication Number Publication Date
JP3946239B1 true JP3946239B1 (en) 2007-07-18
JP2008013443A JP2008013443A (en) 2008-01-24

Family

ID=38344679

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006183236A Active JP3946239B1 (en) 2006-07-03 2006-07-03 Accelerating pulse wave aging index raising agent

Country Status (1)

Country Link
JP (1) JP3946239B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1938866A2 (en) * 2006-12-22 2008-07-02 Nippon Barrier Free Co. Ltd. Cosmetic product comprising a component extracted from a Salmonidae fish ovarian
JP2012255036A (en) * 2012-10-02 2012-12-27 Nippon Barrier Free:Kk Anti-aging agent

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1938866A2 (en) * 2006-12-22 2008-07-02 Nippon Barrier Free Co. Ltd. Cosmetic product comprising a component extracted from a Salmonidae fish ovarian
EP1938866A3 (en) * 2006-12-22 2009-04-08 Nippon Barrier Free Co. Ltd. Cosmetic product comprising a component extracted from a Salmonidae fish ovarian
JP2012255036A (en) * 2012-10-02 2012-12-27 Nippon Barrier Free:Kk Anti-aging agent

Also Published As

Publication number Publication date
JP2008013443A (en) 2008-01-24

Similar Documents

Publication Publication Date Title
Lin et al. Angiotensin-I-converting enzyme (ACE)-inhibitory and antihypertensive properties of squid skin gelatin hydrolysates
Shim et al. Inhibitory effect of aqueous extract from the gall of Rhus chinensis on alpha-glucosidase activity and postprandial blood glucose
Cesur et al. A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting
Johnston et al. Vinegar: medicinal uses and antiglycemic effect
CN1026064C (en) Preparation process for composite inhibiting activated
EP3231437B1 (en) Aging inhibitor
RU2606154C2 (en) Lixisenatide as add-on therapy to basal insulin in type 2 diabetes
RU2546520C2 (en) Application of ave0010 for production of medication for treatment of type 2 diabetes mellitus
KR100633503B1 (en) a Process for Manufacturing the Fermented Materials
DK2328858T3 (en) Drink comprehensive hydroxybutyrate ester and its medical use
ES2723887T3 (en) Fixed ratio formulation of insulin glargine / lixisenatide
CN102224891B (en) Sugar alcohol honey apple jam and preparation method thereof
CN102292093B (en) Composition from sphaeranthus indicus and garcinia mangostana for the control of metabolic syndrome
JP2005213227A (en) Use of blood sugar increase suppressing effect of d-psicose
US20100150890A1 (en) Medicinal composition, food or drink having effect of enhancing sympathetic nervous activity
JP2005514342A (en) Medicinal-food preparations with nutritional and nutritional enhancement
JP4561098B2 (en) Diabetes medicine
CN104957610B (en) A kind of plant enzyme and its production and use
JPH09512552A (en) Methods and compositions for treating renal diseases and disorders
PT2763690E (en) Lixisenatide for use in the treatment of stenosis or/and obstruction in the pancreatic duct system
Stranden et al. Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin.
Ishikawa et al. Rice protein hydrolysates stimulate GLP-1 secretion, reduce GLP-1 degradation, and lower the glycemic response in rats
JP6227519B2 (en) Leucine-rich peptide composition and isolation method
KR20050087817A (en) Remedy
KR20030070029A (en) Remedies for diabetes

Legal Events

Date Code Title Description
TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20070320

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20070410

R150 Certificate of patent or registration of utility model

Ref document number: 3946239

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100420

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110420

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120420

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130420

Year of fee payment: 6

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140420

Year of fee payment: 7

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250